SCHEMBL4501475

SCHEMBL4501475

CC1CC(C)CN(CCCC(=O)c2ccc(F)cc2)C1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD3 P35462 2/20 0.71
MEN1 O00255 1/20 0.71
CHRM2 P08172 1/20 0.71
HTR1A P08908 1/20 0.71
ADRA2A P08913 1/20 0.71
DRD1 P21728 1/20 0.71
ADRA1A P35348 1/20 0.71
OPRM1 P35372 1/20 0.71
KMT2A Q03164 1/20 0.71
KCNH2 Q12809 1/20 0.71
HRH3 Q9Y5N1 1/20 0.71
TSHR P16473 1/20 0.63
DRD2 P14416 4/20 0.59
DRD4 P21917 1/20 0.59
KDM4E B2RXH2 1/20 0.58
HSD17B10 Q99714 1/20 0.58
NPC1 O15118 1/20 0.54
RAB9A P51151 1/20 0.54
CYP2D6 P10635 1/20 0.54
HTR2A P28223 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20652684 0.84 CYP2J2 (0.57) DRD3MEN1CHRM2HTR1AADRA2A
Melperone SCHEMBL146287 0.83 KMT2A (1.00) DRD3MEN1CHRM2HTR1AADRA2A
SCHEMBL4510032 0.83 DRD3 (0.51) DRD3MEN1CHRM2HTR1AADRA2A
Nonaperone SCHEMBL2109345 0.83 DRD3 (0.67) DRD3MEN1CHRM2HTR1AADRA2A
Melperone SCHEMBL1649537 0.82 KMT2A (0.97) DRD3MEN1CHRM2HTR1AADRA2A
SCHEMBL20652958 0.82 CYP2J2 (0.56) DRD3MEN1CHRM2HTR1AADRA2A
SCHEMBL10370210 0.80 DRD3 (0.56) DRD3MEN1CHRM2HTR1AADRA2A
SCHEMBL10370891 0.80 DRD3 (0.59) DRD3MEN1CHRM2HTR1AADRA2A
SCHEMBL16986166 0.78 TSHR (0.97) DRD3MEN1CHRM2HTR1AADRA2A
SCHEMBL27541728 0.78 DRD3 (0.46) DRD3MEN1CHRM2HTR1AADRA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7485651-B2 Compounds with activity on muscarinic receptors ACADIA PHARMACEUTICALS, INC. (US) 2009-02-03 US disclosed
US-20080108618-A1 COMPOUNDS WITH ACTIVITY ON MUSCARINIC RECEPTORS BRANN MARK 2008-05-08 US disclosed
US-20030144285-A1 Compounds with activity on muscarinic receptors BRANN MARK (US) 2003-07-31 US disclosed
US-6528529-B1 4-Methoxy-1-(4-(2-methylphenyl)-4-oxo-1-butyl)piperidine ACADIA PHARMACEUTICALS INC. 2003-03-04 US disclosed
CN-1303376-A Compound with activity on muscarinic receptors ACADIA PHARMACEUTICAL INC (US) 2001-07-11 CN disclosed
WO-2001005763-A2 COMPOUNDS WITH ACTIVITY ON MUSCARINIC RECEPTORS ACADIA PHARMACEUTICALS, INC. (US) 2001-01-25 WO disclosed
EP-1068185-A1 COMPOUNDS WITH ACTIVITY ON MUSCARINIC RECEPTORS Acadia Pharmaceuticals Inc. (US) 2001-01-17 EP disclosed
WO-1999050247-A1 COMPOUNDS WITH ACTIVITY ON MUSCARINIC RECEPTORS ACADIA PHARMACEUTICALS, INC. (US) 1999-10-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080108618-A1 COMPOUNDS WITH ACTIVITY ON MUSCARINIC RECEPTORS CHRM3, CHRM2, CHRM1 DRD3 687/4885MEN1 539/4885CHRM2 2/4885
US-20030144285-A1 Compounds with activity on muscarinic receptors CHRM3, CHRM2, CHRM1 DRD3 687/4885MEN1 539/4885CHRM2 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.